Background. Alzheimer’s disease (AD) is a neurodegenerative condition affecting memory performance. This pathology is characterized by intracerebral amyloid plaques and tau tangles coupled with neuroinflammation. During the last century, numerous therapeutic trials, targeting amyloid, tau or neuroinflammation, unfortunately failed. Development of new therapeutic approaches for AD is eagerly awaited. In this study, we propose to test the use of low-dose brain radiotherapy (LD-RT). LD-RT showed efficacy to reduce amyloid load in patients with peripheral pathologies and also presents anti-inflammatory effects in patients with systemic inflammatory diseases. Furthermore, previous evidence showed an effect on amyloid load, memory performance and modulation of the immune response in AD mice. Methods. The hemi-brain of 14-15 months old TgF344-AD rats was irradiated with two LD-RT schedules (5 fractions of 2 Gy, delivered weekly or daily). Rats underwent behavioral tests to assess memory and general locomotion, before and/or 4 months post treatment. LD-RT impact on amyloid and neuroinflammation was measured using immunohistology.Results. An improvement of spatial working memory was observed in the daily treated group but not in animals treated weekly. On the other hand, both LD-RT schedules were unable to impact amyloid load. An increase of astrocyte reactivity was observed in TgAD groups compared to wild-type animals but LD-RT did not impact it. The weekly treatment increased CD68+ microglial density in the molecular layer of the hippocampus but no effect was observed with the daily treatment. One major limitation of this study was the already well-established amyloid pathology, which was probably too advanced to observe a potential decrease. Nevertheless, we observed a memory improvement, the main cognitive symptoms of AD, after daily treatment, offering encouraging data to further evaluate the LD-RT therapeutic potential. Conclusions. This study showed a biological effect of LD-RT in an AD rat model on memory performance (after daily treatment) and microglial density (after weekly treatment). The lack of effect of both regimens on amyloid pathology, unexpected, was possibly due to the advanced pathology of our animals. The positive effect on cognition encourages to further evaluate the LD-RT therapeutic potential at an earlier AD stage.